氯吡格雷联合丹参酮Ⅱa磺酸钠治疗心肌缺血-再灌注损伤的临床价值评价

Evaluation on Clinical Value of Clopidogrel and Sodium Tanshinon Ⅱa Silate in Treatment of Myocardial Ischemia-reperfusion Injury

目的探讨氯吡格雷联合丹参酮Ⅱa磺酸钠治疗心肌缺血-再灌注损伤的临床价值评价。方法参与研究的94例患者,从2017年5月—2018年5月收治的入院接受治疗的心肌缺血-再灌注损伤患者,按照随机数字法,将94例患者分为两组,接受氯吡格雷的患者为对照组,接受氯吡格雷联合丹参酮Ⅱa磺酸钠治疗的患者为观察组,两组患者在接受不同的治疗模式,观察对比两组患者的CPK、CK-MB水平、LVEDD、LVEF指标。结果治疗前,观察组患者与对照组患者的CPK、CK-MB水平、LVEDD、LVEF无明显差异,组间数据差异无统计学意义(P>0.05);治疗后,观察组患者的CPK (150.29±15.29)U/L、CK-MB(20.57±3.75)U/L水平低于对照组患者CPK(200.85±16.28)U/L、CK-MB(43.83±8.22)U/L水平,观察组患者的LVEDD(51.93±3.84)mm、LVEF水平(48.28±7.23)%高于对照组患者的LVEDD(47.48±3.95)mm、LVEF水平(48.39±2.85)%,观察组患者的治疗效果明显优于对照组患者,数据差异有统计学意义(t_1=14.312 3,t_2=8.141 3,t_3=13.522 4,t_4=5.256 3,P<0.05)。结论心肌缺血-再灌注损伤患者接受氯吡格雷联合丹参酮Ⅱa磺酸钠治疗,能有效的改善患者的心功能,降低CPK、CK-MB水平,保护患者的心肌细胞,促进疾病的好转,值得推广。

Objective To study the clinical value of clopidogrel and sodium tanshinonⅡa silate in treatment of myocardial ischemia-reperfusion injury.Methods 94 cases of patients with myocardial ischemia-reperfusion injury treated in our hospital from May 2017 to May 2018 were selected and randomly divided into two groups,the control group were treated with clopidogrel,while the observation group were treated with sodium tanshinonⅡa silate,and the CPK,CK-MB levels,LVEDD,LVEF of the two groups were observed and compared.Results Before treatment,there were no obvious differences in the CPK,CK-MBlevel,LVEDD,LVEF between the two groups,without statistical significance(P>0.05),after treatment,the CPK(150.29±15.29)U/L,CK-MB(20.57±3.75)U/L levels in the observation group were lower than those in the control group,CPK(200.85±16.28)U/L,CK-MB(43.83±8.22)U/L,and the LVEDD(51.93±3.84)mm,LVEF level(48.28±7.23)%in the observation group were higher than those in the control group LVEDD(47.48±3.95)mm,LVEF level(48.39±2.85)%,and the treatment effect in the observation group was obviously better than that in the control group and the differences were statistically significant(t1=14.312 3,t2=8.141 3,t3=13.522 4,t4=5.256 3,P<0.05).Conclusion The clopidogrel and sodium tanshinonⅡa silate in treatment of myocardial ischemia-reperfusion injury can effectively improve the cardiac function,reduce the CPK,CK-MB levels,protect the cardiac muscle cells and promote the improvement of diseases,and it is worth promotion.